When the Arbitration Office Must Decide

Last Resort for Reimbursement of New Drugs in Germany

Authors: Glüsen M, Rehkopf J, Martyniszyn-Eiben A, Kielhorn-Schönermark H, Schönermark M

Poster presentation at ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Objectives:

After the benefit resolution of the German health technology assessment (AMNOG) for new drugs, the pharmaceutical companies negotiate with the Sickness Funds about reimbursement amounts and general conditions. If no agreement is achieved, an arbitration procedure (AP) must be initiated, and the reimbursement amount is determined by the arbitration office. The aim of this study was to analyze the APs regarding benefit assessment ratings, rebate outcomes, and market exit after arbitral verdict to examine the impact on and of the AP.

Methods:

The results of AMNOG procedures with a subsequent AP on reimbursement amounts were compared with all other AMNOG procedures without an AP using a database containing relevant information of all AMNOG procedures ever conducted. Using the Lauer-Taxe, drug availability on the German market was verified.

Results:

No relevant differences in the distribution of benefit levels between procedures with and without AP could be identified. Net box rebates were on average higher after an AP, both for procedures with added benefit ratings (36% vs. 27%) and without (62% vs. 33%). In 19 out of 54 APs, the drug exited the German market after arbitral verdict. Moreover, 14 of those 19 drugs did not receive an additional benefit in the benefit assessment and the arbitration office decided on an average net box rebate of 75%.

Conclusions:

The appointed level of benefit for a drug in the benefit resolution had no influence on whether the arbitration office was involved. However, undergoing the AP leads on average to higher rebates for drugs, i.e., APs seem to be decided to the disadvantage of pharmaceutical companies. These high rebates lead to a significantly increased withdrawal rate from the German market. The reimbursement amount, which is highly dependent on the benefit level, seems to correlate with the frequency of market withdrawals.

Get in touch

Ihr Ansprechpartner  Malte Glüsen
Malte Glüsen
M. Sc. Molecular Microbiology
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

Download

Here you can download our poster presentations free of charge.

Last Resort for Reimbursement of New Drugs in Germany: When the Arbitration Office Must Decide

Strategic Pricing & Pricing Negotiations


Gain confidence for your decisions with us! We analyze with you individual pricing mechanisms and the European reference price system.

Market Access Strategy


We can build your sound market access strategy at an early stage, giving you and all parties involved valuable orientation throughout the entire market access process.
to the top